Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
VAMAS6
MCID: VTL009
MIFTS: 42

Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 (VAMAS6)

Categories: Genetic diseases, Immune diseases, Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

About this section

MalaCards integrated aliases for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

Name: Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 56 13
Generalized Vitiligo 73 71
Vitiligo 73 71
Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 71
Vamas6 56
Vtlg 73

Characteristics:

OMIM:

56
Inheritance:
? epistatically interacting multiple autosomal recessive


HPO:

31
vitiligo-associated multiple autoimmune disease susceptibility 6:
Inheritance autosomal recessive inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Skin diseases Immune diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM 56 193200
MeSH 43 D014820
UMLS 71 C0042900 C1304470 C1847835
Sources

Summaries for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

About this section
UniProtKB/Swiss-Prot : 73 Vitiligo: A pigmentary disorder of the skin and mucous membranes. It is characterized by circumscribed depigmented macules and patches, commonly on extensor aspects of extremities, on the face or neck and in skin folds. Vitiligo is a progressive disorder in which some or all of the melanocytes in the affected skin are selectively destroyed. It is a multifactorial disorder with a complex etiology probably including autoimmune mechanisms, and is associated with an elevated risk of other autoimmune diseases.

MalaCards based summary : Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6, also known as generalized vitiligo, is related to vitiligo-associated multiple autoimmune disease susceptibility 1 and deafness, congenital, with vitiligo and achalasia, and has symptoms including pruritus and exanthema. An important gene associated with Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 is PTPN22 (Protein Tyrosine Phosphatase Non-Receptor Type 22). The drugs Pimecrolimus and mometasone furoate have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and thyroid, and related phenotypes are vitiligo and nevus

More information from OMIM: 193200
Sources

Related Diseases for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

About this section

Diseases in the Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 family:

Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 609)
# Related Disease Score Top Affiliating Genes
1 vitiligo-associated multiple autoimmune disease susceptibility 1 13.1
2 deafness, congenital, with vitiligo and achalasia 12.6
3 alopecia universalis onychodystrophy vitiligo 12.4
4 obsolete: vitiligo-associated autoimmune disease 12.3
5 vitiligo, progressive, with mental retardation and urethral duplication 12.3
6 spastic paraplegia 23, autosomal recessive 12.2
7 autoimmune disease 1 12.1
8 alopecia areata 11.8
9 alezzandrini syndrome 11.7
10 autoimmune disease 2 11.6
11 autoimmune disease 3 11.6
12 autoimmune disease 4 11.6
13 schrander-stumpel theunissen hulsmans syndrome 11.6
14 vogt-koyanagi-harada disease 11.6
15 autoimmune polyendocrine syndrome, type i, with or without reversible metaphyseal dysplasia 11.6
16 autoimmune polyglandular syndrome type 3 11.6
17 halo nevi 11.5
18 hypoadrenocorticism, familial 11.4
19 hemifacial atrophy, progressive 11.4
20 autoimmune atrophic gastritis 11.4
21 stiff-person syndrome 11.3
22 familial cold autoinflammatory syndrome 3 11.3
23 hereditary spastic paraplegia 23 11.2
24 ermine phenotype 11.1
25 combined cellular and humoral immune defects with granulomas 11.1
26 nijmegen breakage syndrome 11.1
27 lelis syndrome 11.1
28 t-cell receptor-alpha/beta deficiency 11.1
29 hypopigmentation of eyelid 11.1
30 gemignani syndrome 11.1
31 pigmentation anomaly of the skin 11.1
32 autoimmune disease 10.9
33 skin disease 10.8
34 alopecia 10.8
35 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.7
36 psoriasis 10.7
37 pustulosis of palm and sole 10.7
38 melanoma 10.6
39 thyroiditis 10.6
40 hypothyroidism 10.6
41 dowling-degos disease 1 10.5
42 dermatitis 10.5
43 dermatitis, atopic 10.5
44 skin carcinoma 10.5
45 hashimoto thyroiditis 10.4
46 lichen planus 10.4
47 thyroid gland disease 10.4
48 pernicious anemia 10.4
49 graves' disease 10.4
50 uveitis 10.3

Graphical network of the top 20 diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:



Diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6
Sources

Symptoms & Phenotypes for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

About this section

Human phenotypes related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

31
# Description HPO Frequency HPO Source Accession
1 vitiligo 31 HP:0001045
2 nevus 31 HP:0003764

Symptoms via clinical synopsis from OMIM:

56
Skin:
vitiligo
halo nevi

Misc:
onset after birth
no predilection for ventral skin

Clinical features from OMIM:

193200

UMLS symptoms related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:


pruritus, exanthema
Sources

Drugs & Therapeutics for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

About this section

Drugs for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 138)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pimecrolimus Approved, Investigational Phase 4 137071-32-0 6447131 17753757
2
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
3
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
4
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538 444795
5 Amotosalen Phase 4
6 Ficusin Phase 4
7 Furocoumarins Phase 4
8 Neurotransmitter Agents Phase 4
9 Acetylcholine Release Inhibitors Phase 4
10 Botulinum Toxins Phase 4
11 abobotulinumtoxinA Phase 4
12 Neuromuscular Agents Phase 4
13 Cholinergic Agents Phase 4
14 Botulinum Toxins, Type A Phase 4
15
Zinc Approved, Investigational Phase 3 7440-66-6 32051
16
Zinc sulfate Approved, Investigational Phase 3 7733-02-0
17
Latanoprost Approved, Investigational Phase 2, Phase 3 130209-82-4 5282380 5311221
18
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 445643 439492 6473866
19
Triamcinolone Approved, Vet_approved Phase 2, Phase 3 124-94-7 31307
20 Protective Agents Phase 3
21 Adjuvants, Immunologic Phase 3
22 Viscosupplements Phase 3
23 Trace Elements Phase 3
24 Micronutrients Phase 3
25 Nutrients Phase 3
26 Dermatologic Agents Phase 3
27 Janus Kinase Inhibitors Phase 3
28 insulin Phase 3
29 Insulin, Globin Zinc Phase 3
30 Astringents Phase 3
31 Immunosuppressive Agents Phase 2, Phase 3
32 Calcineurin Inhibitors Phase 2, Phase 3
33 Immunologic Factors Phase 2, Phase 3
34 Hormones Phase 2, Phase 3
35 Hormone Antagonists Phase 2, Phase 3
36 Triamcinolone hexacetonide Phase 2, Phase 3
37 triamcinolone acetonide Phase 2, Phase 3
38 Triamcinolone diacetate Phase 2, Phase 3
39 glucocorticoids Phase 2, Phase 3
40
Hydrocortisone acetate Approved, Vet_approved Phase 1, Phase 2 50-03-3
41
Hydrocortisone Approved, Vet_approved Phase 1, Phase 2 50-23-7 5754
42
Etanercept Approved, Investigational Phase 2 185243-69-0
43
Afamelanotide Approved, Investigational Phase 2 75921-69-6
44
Apremilast Approved, Investigational Phase 2 608141-41-9 11561674
45
Simvastatin Approved Phase 1, Phase 2 79902-63-9 54454
46
Atorvastatin Approved Phase 1, Phase 2 134523-00-5 60823
47
Pembrolizumab Approved Phase 2 1374853-91-4
48
Durvalumab Approved, Investigational Phase 2 1428935-60-7
49
Calcium Approved, Nutraceutical Phase 1, Phase 2 7440-70-2 271
50
Bavituximab Investigational Phase 2 648904-28-3

Interventional clinical trials:

(show top 50) (show all 145)
# Name Status NCT ID Phase Drugs
1 Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis) Unknown status NCT01082393 Phase 4 topical tacrolimus treatment;topical pimecrolimus treatment;local mometasone furoate treatment;cold cream
2 Comparison the Efficacy and Safety of 0.1% Tacrolimus Ointment With 0.1% Mometasone Furoate Cream in the Treatment of Adult Vitiligo: A Single Blinded Pilot Study Unknown status NCT01333410 Phase 4 tacrolimus ointment;Mometasone furoate
3 Autologous Punch Grafting in Vitiligo Patients: the Effect of Punchdepth and Punchsize Unknown status NCT01377077 Phase 4
4 Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients: a Randomized Controlled Pilot Study Unknown status NCT01640678 Phase 4
5 Effect of Fluticasone Proprionate 0.05% Cream on Narrow Band UV-B Phototherapy in Active Vitiligo: a Randomised Single Blinded Controlled Trial Unknown status NCT01246921 Phase 4 Fluticasone proprionate 0.05% cream
6 Prospective Open Parallel Right to Left Bilateral Study Comparing Narrowband Ultraviolet B Alone Versus Narrowband Ultraviolet B and Psoralen Plus Ultraviolet A for the Treatment of Vitiligo Completed NCT01732965 Phase 4
7 Botulinum Toxin Treatment for Localized Vitiligo Completed NCT01051687 Phase 4 Botulinum toxin A
8 Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients: a Randomized Controlled Study on the Recipient Site Preparation Completed NCT02458417 Phase 4
9 Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo Recruiting NCT03199664 Phase 4
10 Bimatoprost 0.03% Solution, NB-UVB and Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo Not yet recruiting NCT03487042 Phase 4 Bimatoprost 0.03% ophthalmic solution
11 Efficacy and Safety of Topical Bimatoprost Solution 0.03% in Stable Vitiligo:A Preliminary Study Withdrawn NCT01202513 Phase 4 Bimatoprost 0.03% topical ophthalmic solution
12 Efficacy of Tacrolimus Ointment 0.1% Versus Placebo in Adults With Facial Non-segmental Vitiligo: a Randomized Double-blind Controlled Study Unknown status NCT02466997 Phase 3 tacrolimus;Placebo
13 Continuative vs Sequential Phototherapy in Non-segmental Vitiligo Patients Unknown status NCT00525395 Phase 3
14 Safety and Efficacy of Melanocyte-keratinocyte Transplantation in the Treatment of Vitiligo Completed NCT00830713 Phase 3
15 Comparative Study of 308nm Excimer Lamp and 308nm Excimer Laser in the Treatment of Vitiligo Completed NCT00696358 Phase 3
16 A Multicenter Double-blind Placebo-controlled Trial of Non-cultured Epidermal Cellular Grafting Versus Hyaluronic Acid for Repigmenting Stable Leukoderma (Vitiligo and Piebaldism) Completed NCT02156427 Phase 3
17 Treatment of Vitiligo With Narrowband UVB (TL01) Combined With Tacrolimus (0.1%) Versus Placebo Ointment, a Randomized Right/Left Double Blind Comparative Study Completed NCT00807690 Phase 3 Tacrolimus ointment
18 Autologous Transplantation of Melanocytes for Treatment of Vitiligo Skin Completed NCT00631865 Phase 3
19 Efficacy and Tolerance of Transplantation of Harvested Epidermal Cells and Narrow-Band UVB in Vitiligo Completed NCT01629979 Phase 2, Phase 3
20 Interest of the Dermabrasion by Laser Erbium in the Treatment of the Vitiligo Completed NCT01087216 Phase 2, Phase 3 Bras B : The group control
21 Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo Recruiting NCT04052425 Phase 3 Ruxolitinib cream;Vehicle
22 Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo Recruiting NCT04057573 Phase 3 Ruxolitinib cream;Vehicle
23 Intralesional Candidal Antigen Versus Intralesional Zinc Sulphate in Treatment of Cutaneous Warts, A Randomized Clinical Trial Recruiting NCT03158168 Phase 3 Candida Antigen;Zinc Sulfate
24 Effectiveness of Microneedling and Topical Latanoprost in Treatment of Acrofacial Vitiligo Not yet recruiting NCT03611348 Phase 2, Phase 3 Latanoprost
25 Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo Terminated NCT02191748 Phase 2, Phase 3 Triamcinolone
26 Maintenance Treatment of Non Segmental Vitiligo With Tacrolimus Ointment 0.1% Versus Control, Randomized and Double Blind Study Terminated NCT01841008 Phase 2, Phase 3 Protopic;Placebo : Diprobase
27 Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Study of the Efficacy and Safety of ACH24 in the Treatment of Vitiligo Withdrawn NCT01419964 Phase 3 Group 01;Group 02
28 Comparative Study of the Use of Trypsin Versus Dispase in Melanocyte-Keratinocyte Transplantation for the Treatment of Vitiligo Withdrawn NCT01822379 Phase 2, Phase 3
29 Treatment and Complication of Bath PUVA in Vitiligo Unknown status NCT00380471 Phase 2
30 Efficacy of Red Light in Vitiligo: A Prospective, Single-Blind Randomized Controlled Trial Unknown status NCT01787708 Phase 2
31 Efficacy and Safety of Intralesional Triamcinolone Acetonide in Vitiligo: A Prospective, Double-Blind Randomized Controlled Trial Unknown status NCT01766609 Phase 2 Triamcinolone Acetonide
32 UVA 1 Phototherapy for Vitiligo Unknown status NCT01787695 Phase 2
33 Effectivness of Topical Tacrolimus 0.03% Monotherapy in Patients With Vitiligo: Arandomized Controlled Trial Unknown status NCT03358082 Phase 1, Phase 2 Tacrolimus 0.03% Ointment;Hydrocortisone Acetate 1% Ointment
34 Topical Psoralen Ultraviolet Light A Versus Narrow Band Ultraviolet Light B Treatment for Recalcitrant Dermatoses of the Hand: A Prospective Randomized, Single-blinded Controlled Clinical Trial Unknown status NCT01792245 Phase 2
35 A Phase-II, Randomized, Placebo-controlled Trial of Simvastatin in Generalized Vitiligo Completed NCT01517893 Phase 2 Simvastatin;Placebo
36 Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris Completed NCT00372307 Phase 2 Application of pimecrolimus
37 Pilot, Investigator-Initiated, Proof-of-Concept, Study of the Efficacy and Safety of Etanercept (Enbrel) in Adults With Vitiligo Completed NCT00134368 Phase 2 Etanercept
38 A Phase II Randomised Pilot Study to Compare the Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo Completed NCT01382589 Phase 2 Afamelanotide
39 Open Label Phase 2 Proof-of-concept Pilot Trial of Topical Ruxolitinib in Repigmenting Adult Patients With Vitiligo Completed NCT02809976 Phase 2 Ruxolitinib 1.5% Phosphate Cream
40 Study of Applications of Autologous Epidermal Cells in Liquid Phase in the Treatment of Vitiligo Completed NCT01511965 Phase 1, Phase 2
41 Phase I-II, Randomized, Intraindividually Placebo Controlled Clinical Trial, to Evaluate the Efficacy of Autologous Melanocyte Transplantion on Amniotic Membrane as a Substrate for Patients With Stable Vitiligo. Completed NCT01701648 Phase 1, Phase 2
42 Atorvastatin in Active Vitiligo: a Bicentric Prospective Randomized Trial Completed NCT02432534 Phase 2 Atorvastatin
43 A Split Body Study of the Effects of Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo Completed NCT03123016 Phase 2 Apremilast
44 Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO RAPID VITILIGO Completed NCT03036995 Phase 2 Apremilast
45 A Phase 2a, Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Safety, Tolerability, and Systemic Exposure of Cerdulatinib Gel, 0.37% in Adults With Vitiligo Recruiting NCT04103060 Phase 2 Cerdulatinib 0.37% gel;Vehicle gel
46 The Evaluation of Vitiligous Lesions Repigmentation After the Administration of Atorvastatin Calcium Salt and Simvastatin-acid Sodium Salt in Patients With Active Vitiligo (EVRAAS) Recruiting NCT03247400 Phase 1, Phase 2 1% simvastatin-acid sodium salt ointment;1% atorvastatin calcium salt ointment
47 A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 WITH A PARTIALLY BLINDED EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF PF-06651600 AND PF-06700841 IN SUBJECTS WITH ACTIVE NON-SEGMENTAL VITILIGO Recruiting NCT03715829 Phase 2 PF-06651600;PF-06651600;PF-06651600;PF-06651600;PF-06651600;placebo;PF06700841
48 A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting NCT03076554 Phase 2 Avelumab
49 A Phase II Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma Recruiting NCT03519997 Phase 2 Pembrolizumab;Bavituximab
50 A Randomized, Double-Blind, Dose-Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo Active, not recruiting NCT03099304 Phase 2 Ruxolitinib cream;Vehicle cream

Search NIH Clinical Center for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Methoxsalen
monobenzone
Trioxsalen
Sources

Genetic Tests for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

About this section
Sources

Anatomical Context for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

About this section

MalaCards organs/tissues related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

40
Skin, T Cells, Thyroid, Liver, Testes, Eye, Lung
Sources

Publications for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

About this section

Articles related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

(show top 50) (show all 6688)
# Title Authors PMID Year
1
Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. 61 56
20526339 2010
2
Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. 61 56
20410501 2010
3
Vitiligo: complex segregation and linkage disequilibrium analyses with respect to microsatellite loci spanning the HLA. 61 56
11941482 2002
4
Predominant role of innate pro-inflammatory cytokines in vitiligo disease. 61
31620869 2020
5
The Epidemiology and Clinical Manifestations of Autoimmunity in Selective IgA Deficiency. 61
31267472 2020
6
Vitiligo: Mechanisms of Pathogenesis and Treatment. 61
32017656 2020
7
Clinical and epidemiological characteristics of childhood vitiligo: a study of 701 patients from Brazil. 61
31544238 2020
8
Vitiligo following stem-cell transplant. 61
31358916 2020
9
Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: a single-institution retrospective study. 61
31095037 2020
10
The association between vitamin deficiency and otolaryngologic diseases: A therapeutic target. 61
31733530 2020
11
Advances in fluorescent probes for detection and imaging of endogenous tyrosinase activity. 61
32035843 2020
12
Psychological disturbances in patients with pigmentary disorders: a cross-sectional study. 61
31566833 2020
13
Emerging drugs for the treatment of vitiligo. 61
31958256 2020
14
Comparative analysis of the body surface area calculation method used in vitiligo extent score vs the hand unit method used in vitiligo area severity index. 61
32017422 2020
15
Occurrences and Outcomes of Immune Checkpoint Inhibitors-Induced Vitiligo in Cancer Patients: A Retrospective Cohort Study. 61
31630381 2020
16
The effects of UVB irradiance on vitiligo phototherapy and UVB-induced photocarcinogenesis. 61
32022939 2020
17
Evaluating prevalence of depression, anxiety and hopelessness in patients with Vitiligo on an Iranian population. 61
32013982 2020
18
Phenotype and function of circulating memory T cells 1 in human vitiligo. 61
32012221 2020
19
Efficacy of microneedling combined with tacrolimus versus either one alone for vitiligo treatment. 61
32030880 2020
20
Activated NLR family pyrin domain containing 3 (NLRP3) inflammasome in keratinocytes promotes cutaneous T-cell response in patients with vitiligo. 61
31756352 2020
21
Identification of CD49a+ CD8+ resident memory T cells in vitiligo-like lesions associated with nivolumab treatment for melanoma. 61
31571305 2020
22
ATP-P2X7-induced inflammasome activation contributes to melanocyte death and CD8+ T-cell trafficking to the skin in vitiligo. 61
32035094 2020
23
ΜicroRNA‑421 participates in vitiligo development through regulating human melanocyte survival by targeting receptor‑interacting serine/threonine kinase 1. 61
31974624 2020
24
Author Correction: Micro RNAs upregulated in Vitiligo skin play an important role in its aetiopathogenesis by altering TRP1 expression and keratinocyte-melanocytes cross-talk. 61
32015404 2020
25
Melanoma to Vitiligo: The Melanocyte in Biology & Medicine-Joint Montagna Symposium on the Biology of Skin/PanAmerican Society for Pigment Cell Research Annual Meeting. 61
31348921 2020
26
Rituximab treatment for dermatitis herpetiformis in the setting of type 1 diabetes mellitus, celiac disease, vitiligo, autoimmune hemolytic anemia, and autoimmune thrombocytopenia. 61
32016156 2020
27
Late-onset interstitial nephritis in a patient with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. 61
31840853 2020
28
Nicastrin Deficiency Induces Tyrosinase-Dependent Depigmentation and Skin Inflammation. 61
31437444 2020
29
Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events. 61
31233857 2020
30
Local heroes or villains: tissue-resident memory T cells in human health and disease. 61
31969685 2020
31
CHARACTERISTICS OF GRAVES' DISEASE IN HIV-INFECTED PATIENTS ON ANTIRETROVIRAL THERAPY. 61
31968184 2020
32
Genital vitiligo in children: Factors associated with generalized, non-segmental vitiligo. 61
31682011 2020
33
Immunopathological manifestations in Kabuki syndrome: a registry study of 177 individuals. 61
31363182 2020
34
The genetic architecture of vitiligo. 61
31743585 2020
35
Onychomatricoma in a Patient With Extensive Vitiligo. 61
30531540 2020
36
Home vs hospital narrowband UVB treatment by a hand-held unit for new-onset vitiligo: A pilot randomized controlled study. 61
31206787 2020
37
Premature cell senescence in human skin: Dual face in chronic acquired pigmentary disorders. 61
31733332 2020
38
Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris. 61
32038878 2020
39
Association of herpes zoster and chronic inflammatory skin disease in United States inpatients. 61
31958523 2020
40
Phototherapy for Vitiligo. 61
31753192 2020
41
Refractory vitiligo improving with eculizumab. 61
31997487 2020
42
Lenticular opacities in vitiligo iridis. 61
31856526 2020
43
Deep Genotype Imputation Captures Virtually All Heritability of Autoimmune Vitiligo. 61
31943001 2020
44
Ultraviolet photography in vitiligo: image quality, validity and reliability. 61
31994253 2020
45
Antimelanocyte Antibodies: A Possible Role in Patients with Vitiligo. 61
32029937 2020
46
Differentiating normal lip fluorescence from vitiligo under Wood's light. 61
31112728 2020
47
Nonsegmental vitiligo follows Blaschko's lines and embryonic pigmentary segments. 61
31898641 2020
48
Effect of narrowband ultraviolet B treatment on micro RNA expression in active non-segmental generalized vitiligo. 61
31975367 2020
49
NPY Gene Polymorphism in Vitiligo: A Case-Control Study in Egyptian Patients. 61
32029945 2020
50
Proceeding Report of the Second Vitiligo International Symposium (VIS)- November 9-10, 2018, Detroit, Michigan, USA. 61
31984599 2020
Sources

Variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

About this section

ClinVar genetic disease variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 KIF1B NM_015074.3(KIF1B):c.4387C>T (p.Arg1463Cys)SNV Uncertain significance 374063 rs757850683 1:10425479-10425479 1:10365421-10365421

UniProtKB/Swiss-Prot genetic disease variations for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

73
# Symbol AA change Variation ID SNP ID
1 PTPN22 p.Arg620Trp VAR_022605 rs2476601

Sources

Expression for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

About this section
Search GEO for disease gene expression data for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6.
Sources

Pathways for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

About this section
Sources

GO Terms for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

About this section
Sources

Sources for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....